Developing Translational Science capabilities to support the delivery of precision medicine at the University of Leicester

Lead Research Organisation: University of Leicester

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50

 
Description Development of Diagnostic Assays for Direct Measurement of Meningococcal Vaccine Antigen Expression in Clinical Samples
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact Potential influence in meningitis vaccine choice depending on the local meningococcal strains and the coverage offered by Men B vaccine vaccines (GSK and Pfizer)
URL https://www.eurekalert.org/pub_releases/2018-06/uol-rfn061818.php
 
Description Primary versus metastasis using Ion Torrent Next Generation Sequencing (PRIMINGS) - Clinical Translation
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
Impact Soon to be implemented in ISO accredited lab space as part of the service provision for local genomic laboratory hub (joint venture between UoL and UHL)
 
Description BHF Clinical Research Training Fellowship: "Prevalence and determinants of sub-clinical cardiac dysfunction in adults with type 2 diabetes"
Amount £275,156 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Breast Cancer Now preclinical catalyst award - Explants
Amount £670,000 (GBP)
Organisation Breast Cancer Now 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2018 
End 05/2021
 
Description Cardiac rest and stress metabolism in patients with Type 2 Diabetes
Amount £136,122 (GBP)
Funding ID FS/18/26/33501 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2018 
End 10/2020
 
Description Development grant - NEK project
Amount £10,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Development of Diagnostic Assays for Direct Measurement of Meningococcal Vaccine Antigen Expression in Clinical Samples
Amount £790,000 (GBP)
Funding ID MR/S007490/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 04/2019 
End 03/2021
 
Description Development of capture matrix and package for detection and diagnosis of respiratory disorders using mask
Amount £22,000 (GBP)
Organisation University of Leicester 
Sector Academic/University
Country United Kingdom
Start 12/2018 
End 07/2019
 
Description Evaluation of a Mask Aerosol Sampling System (MASS) as an Active Case Finding Approach Focused on Infectious TB in Low-Resource Settings.
Amount £151,592 (GBP)
Funding ID MR/S002278/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2018 
End 03/2020
 
Description Explant collaboration with LifeArc
Amount £320,000 (GBP)
Organisation LifeArc 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Further LifeArc funding for Explant project
Amount £170,000 (GBP)
Organisation LifeArc 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Heart failure in type 2 diabetes: improving diagnosis and management in a multi-ethnic population.
Amount £1,950,000 (GBP)
Funding ID RP-2017-08-ST2-007 
Organisation National Institute of Health Research and Development (NIHRD) 
Sector Public
Country Indonesia
Start  
 
Description LPMI Capacity Building Call - TMAO Study
Amount £30,000 (GBP)
Organisation University of Leicester 
Sector Academic/University
Country United Kingdom
Start  
 
Description Leicester Precision Medicine Institute studentship
Amount £75,000 (GBP)
Organisation University of Leicester 
Department Leicester Precision Medicine Institute
Sector Hospitals
Country United Kingdom
Start  
 
Description MRC Biomedical Catalyst: Developmental Pathway Funding Scheme (DPFS) - LifeMap
Amount £1,000,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 07/2019 
 
Description Mask aerosol sampling system for the diagnosis of respiratory infections
Amount £60,000 (GBP)
Organisation The Henry Smith Charity 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Prevalence and determinants of subclinical cardiovascular dysfunction in adults with Type 2 Diabetes Mellitus
Amount £275,156 (GBP)
Funding ID FS/16/47/32190 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2017 
End 07/2020
 
Description The Integrative Midlands Partnership for Biomedical Training (IMPACT) - Explants
Amount £100,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start  
 
Description iCase student funded through LifeArc - Sin3A project
Amount £26,000 (GBP)
Organisation LifeArc 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2019 
 
Description sLoLa: basic research grant awarded to study splicing mechanisms
Amount £3,700,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start  
 
Title Explant Project 
Description Using an ex vivo tissue explant to model patient responses to standard of care and novel drug therapies 
Type Of Material Model of mechanisms or symptoms - human 
Year Produced 2015 
Provided To Others? Yes  
Impact MCR Toxicology (Leicester) and the University of Leicester have worked in collaboration to develop the model to its current format (since 2007). The collaboration with CRT began in 2015 and encompasses access to individuals and facilities at CRT-DL (Cambridge) and work to trial a number of their novel compounds. CRT has continued the collaboration under the name of Cancer Research UK Therapeutic Discovery Laboratories and the MRCT has continued the collaboration under the name of LifeArc. The partnership with LifeArc and CR-UK Therapeutic Discovery Labs to test a range of novel anti-cancer drugs is continuing (for a total of £735,000 until 2021) and has attracted considerable attention from the pharmaceutical industry. Boehringer Ingelheim, Pierre Fabre and Ono Pharmaceuticals are interested in the PDE platform for preclinical drug testing. The pre-clinical model is now used with a wide variety of tumor types from lung to breast cancer, melanoma, colorectal cancer and endometrial cancer. A number of publications have used this methodology (prior to MRC funding) from this source. This project has now produced 3 publications, in addition to several poster presentations with published abstracts, alongside further collaborations with other tech transfer companies. This project has received 3 rounds of follow on CiC funding (MC_PC_14117, MC_PC_15045, MC_PC_16051) - Updated in Feb2020. 
 
Description Cardio Health MRI Scan 
Organisation Resonance Health
Country Australia 
Sector Private 
PI Contribution The patient recruitment and MRI imaging has taken place at Leicester. A proof of concept study adapting Resonance Health's existing algorithm with cardiac gating and acquired images from healthy volunteers and cardiology patients has been completed - with input from both partners.
Collaborator Contribution Resonance Health have developed the algorithm for cardio MRI imaging and will help with analysing the MRI scans.
Impact P2D funding (2016/2017 MC_PC_15056) was awarded to the PI to visit Resonance Health in Perth Australia, and for physicists from Resonance Health to come to Leicester to optimise the MRI sequence. Healthy volunteers and patients have been scanned and analysis of images is underway. Full patient and volunteer recruitment is complete and data analysis is under way with Resonance Health. A publication in a high profile journal is expected in 2021 (delayed due to COVID increased clinical commitments). It is anticipated that the data will inform future imaging diagnostics proposals and will have positive impact on patients to help early disease management for patients susceptible to severe cardiac disease. Updated February 2021.
Start Year 2017
 
Description Development of Diagnostic Assays for Direct Measurement of Meningococcal Vaccine Antigen Expression in Clinical Samples 
Organisation Public Health England
Country United Kingdom 
Sector Public 
PI Contribution PCR based system for the identification of vaccine coverage across menigococcal strains.
Collaborator Contribution PHE - Access to patient derived bacterial DNA from meningitis outbreaks Roche - testing complement-blocking antibodies in meningococcal samples
Impact The relationship enables the testing of vaccine coverage in meningitis outbreaks (real world evidence) enabling validation of the UoL approach and providing data for publications and for the development of data packages to share with pharmaceutical companies (Pfizer and GSK). Publications detailed elsewhere DOIs 10.1128/JCM.00204-18 and 10.1371/journal.pone.0197186 Updated February 2020.
Start Year 2017
 
Description Development of Diagnostic Assays for Direct Measurement of Meningococcal Vaccine Antigen Expression in Clinical Samples 
Organisation Roche Pharmaceuticals
Country Global 
Sector Private 
PI Contribution PCR based system for the identification of vaccine coverage across menigococcal strains.
Collaborator Contribution PHE - Access to patient derived bacterial DNA from meningitis outbreaks Roche - testing complement-blocking antibodies in meningococcal samples
Impact The relationship enables the testing of vaccine coverage in meningitis outbreaks (real world evidence) enabling validation of the UoL approach and providing data for publications and for the development of data packages to share with pharmaceutical companies (Pfizer and GSK). Publications detailed elsewhere DOIs 10.1128/JCM.00204-18 and 10.1371/journal.pone.0197186 Updated February 2020.
Start Year 2017
 
Description Immunomodulation in the Lung by specific inhibition of the Sin3A/HDAC1 complex 
Organisation LifeArc
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Experts in the analysis of HDAC in the epigenetic regulation of disease using molecular and structural biology approaches. Experts in smooth airway biology, asthma and COPD (cellular biology and haematological responses to therapeutics).
Collaborator Contribution LifeArc: Development of novel small molecule inhibitors for neglected disease of clear clinical need. Relationship with Asthma UK and interest in new therapeutics for asthma.
Impact The focus of this project involved the validation of the Sin3A protein as a therapeutic target for the treatment of asthma, and as a result, to work in collaboration with LifeArc and AZ to screen small molecule libraries. To date the validation has been unable to confirm linkage of Sin3A inhibition with the modulation of disease. This work is now supported by a joint iCase studentship with LifeArc (started in April 2019). Has applied to BBSRC (Q1 2020 - £710,000) for follow-up funding using constructs generated in this project. Updated Feb 2020.
Start Year 2017
 
Description Novel kinase target in cancer therapy 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution The aim of this agreement is to develop and use assays for kinase activity to screen an optimised kinase-focused compound collection provided through the AZ Open Innovation Scheme. Depending on the hit matter generated, the plan is to scale-up the established primary and secondary in vitro assays to screen additional targeted AZ compound sets and generate lead compounds, as well as establish cell lines to validate the hit compounds and undertake additional screens.
Collaborator Contribution AZ provides access through their Open Innovation scheme to ~50,000 pre-selected compounds. A more restricted kinase inhibitor set (KIL-set) of ~1,000 compounds will be provided to screen for inhibitors of the kinases studied and understand potential mechanisms of action of these inhibitors in cancer cells. AZ will evaluate hits identified from these screens to determine whether they are appropriate for further investment through computational biology and/or medicinal chemistry, or for limited testing in cell line panels.
Impact The project has used P2D funds (MC_PC_17194) to visit AZ to further screen AZ proprietary compounds using AZ in house high throughput systems. Project update February 2020: Industry-standard, activity-based biochemical screens have been completed. The SAR analysis of the hits has been discussed with AZ. Further collaboration with AZ for oncology drug development is postponed, awaiting for evidences for a link between NEK inhibitors and DNA damage response. Currently, a manuscript is in preparation to publish data package. The targeting of NEK8 is being de-prioritised (lack off suitable molecules and structural biology insights) the tool compounds and data produced to date will be used to write a publication for a high impact journals (within the next 6-8 months). Updated Feb 2020.
Start Year 2017
 
Description Oncogenic splicing factors as novel therapeutic strategies for cancer. 
Organisation European Lead Factory
Country European Union (EU) 
Sector Public 
PI Contribution The compounds will be validated structurally using NMR chemical shift perturbation experiments to identify the binding site of the hit compounds, Isothermal Titration Calorimetry (ITC) to evaluate the stoichiometry, the affinity and the thermodynamic parameters of the interaction.
Collaborator Contribution ELF will screen a library of 450,000 compounds on the splicing factor binding ability and are further evaluated using an orthogonal assay and dose response curves (DRC). A qualified hit list of up to 50 compounds will be supplied for Leicester to further exploit. In parallel, the European screening centre will undertake medicinal chemistry to provide compounds with improved characteristics (Improved Hit List, IHL)
Impact ELF has provided up to 50 compounds which are now being validated at Leicester. The output from this will generate critical preliminary data for future grant applications and/or partnership with companies. ELF are no longer in operation (EU funding finished) and are therefore no longer in a position to support the project. A small number of compounds have been identified but none have significant affinity/specificity combined with desirable phsyico-chemical properties to warrant follow on funding or interest from companies. The project will return to a basic research exercise and may be revisited if suitable novel chemical matter is identified. Updated February 2020.
Start Year 2017
 
Description Probiotics 
Organisation Protexin
Country United Kingdom 
Sector Private 
PI Contribution Assess the ability of a targeted probiotic supplementation to reduce basal/induced levels of a circulating compound that is associated with increased risk of cardiovascular disease.
Collaborator Contribution Protexin supported biostatical analyses of their data to identify the candidate strains that lack one of the key bacterial gene. Furthermore, Protexin produced (at cost to themselves) a multi-strain mixture in an oral capsule form that is produced to GMP quality and suitable for use as dietary supplements for human investigations.
Impact The recruitment of volunteers is complete and mass spectrometry data analysed - data inconclusive due to differential patient responses to Choline supplementation. Inter individual differences presents an opportunity for patient stratification in future studies. Further collaboration with Protexin initiated with a drug/probiotic monitoring project. Applied to BHF for a heart failure patient study (value £200,000) - awaiting for outcome. Updated February 2020
Start Year 2017
 
Description Towards commercialising LifeMap as a novel clinical tool for assessing risk of sudden cardiac death 
Organisation Maddison Product Design
Country United Kingdom 
Sector Private 
PI Contribution Experience in developing novel non-invasive methodologies for the detection of abnormal heart ECG patterns Experience in development of machine learning approaches for automated detecting of abnormal ECGs Assess to patients and data from clincal trails
Collaborator Contribution Mortara - Provision of ECG hardware and software development Renfrew - delivery of ergonomically designed integrated system for the clinical use of LifeMap
Impact 8 Jul 2019 - MRC DPFS grant confirmed for funding, details of award awaited. 15 Jul 2019 - MRC DPFS grant received funding (FEC £1M). DPFS grant with Mortara and Renfrew Group as commercial partners. Updated February 2020
Start Year 2018
 
Description Towards commercialising LifeMap as a novel clinical tool for assessing risk of sudden cardiac death 
Organisation Renfrew Group International
Country United Kingdom 
Sector Private 
PI Contribution Experience in developing novel non-invasive methodologies for the detection of abnormal heart ECG patterns Experience in development of machine learning approaches for automated detecting of abnormal ECGs Assess to patients and data from clincal trails
Collaborator Contribution Mortara - Provision of ECG hardware and software development Renfrew - delivery of ergonomically designed integrated system for the clinical use of LifeMap
Impact 8 Jul 2019 - MRC DPFS grant confirmed for funding, details of award awaited. 15 Jul 2019 - MRC DPFS grant received funding (FEC £1M). DPFS grant with Mortara and Renfrew Group as commercial partners. Updated February 2020
Start Year 2018
 
Description Towards commercialising LifeMap as a novel clinical tool for assessing risk of sudden cardiac death 
Organisation Tactiq
Country United Kingdom 
Sector Private 
PI Contribution Experience in developing novel non-invasive methodologies for the detection of abnormal heart ECG patterns Experience in development of machine learning approaches for automated detecting of abnormal ECGs Assess to patients and data from clincal trails
Collaborator Contribution Mortara - Provision of ECG hardware and software development Renfrew - delivery of ergonomically designed integrated system for the clinical use of LifeMap
Impact 8 Jul 2019 - MRC DPFS grant confirmed for funding, details of award awaited. 15 Jul 2019 - MRC DPFS grant received funding (FEC £1M). DPFS grant with Mortara and Renfrew Group as commercial partners. Updated February 2020
Start Year 2018
 
Description Validation of the efficacy of novel anticancer compounds in primary tumour tissue explants 
Organisation Cancer Research UK
Department CRUK Centre for Cancer Therapeutics
Country United Kingdom 
Sector Private 
PI Contribution Development of a clinically relevant patient-derived tumour tissues primary 3D culture system (Patient-Derived Explant (PDE) technology) to evaluate novel anti-cancer drugs, to assess patient responses to current standard of care treatments. Follow on data show that the model has a strong predictive power in prediction patient responses to therapy and survival.
Collaborator Contribution MCR Toxicology (Leicester) and the University of Leicester have worked in collaboration to develop the model to its current format (since 2007). The collaboration with CRT began in 2015 (with CiC funding from previous award) and encompasses access to individuals and facilities at CRT-DL (Cambridge) and work to trial a number of their novel compounds. CRT will continue the collaboration under the name of Cancer Research UK Therapeutic Discovery Laboratories and the MRCT will continue the collaboration under the name of LifeArc.
Impact The pre-clinical model is now used with a wide variety of tumor types from lung to breast cancer, melanoma, colorectal cancer and endometrial cancer. A number of publications have used this methodology (prior to MRC funding) from this source. This project has now produced 3 publications, in addition to several poster presentations with published abstracts, alongside further collaborations with other tech transfer companies. The partnership with LifeArc and CR-UK Discovery Labs to test a range of novel anti-cancer drugs is continuing (for a total of £735,000 until 2021) and has attracted considerable attention from the pharmaceutical industry. Boehringer Ingelheim, Pierre Fabre and Ono Pharmaceuticals are interested in the PDE platform for preclinical drug testing. This project has received 3 rounds of follow on CiC funding, generating >19-fold return on MRC CiC investment to date (Total £1.7M). Update Feb2020.
Start Year 2016
 
Description Validation of the efficacy of novel anticancer compounds in primary tumour tissue explants 
Organisation LifeArc
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Development of a clinically relevant patient-derived tumour tissues primary 3D culture system (Patient-Derived Explant (PDE) technology) to evaluate novel anti-cancer drugs, to assess patient responses to current standard of care treatments. Follow on data show that the model has a strong predictive power in prediction patient responses to therapy and survival.
Collaborator Contribution MCR Toxicology (Leicester) and the University of Leicester have worked in collaboration to develop the model to its current format (since 2007). The collaboration with CRT began in 2015 (with CiC funding from previous award) and encompasses access to individuals and facilities at CRT-DL (Cambridge) and work to trial a number of their novel compounds. CRT will continue the collaboration under the name of Cancer Research UK Therapeutic Discovery Laboratories and the MRCT will continue the collaboration under the name of LifeArc.
Impact The pre-clinical model is now used with a wide variety of tumor types from lung to breast cancer, melanoma, colorectal cancer and endometrial cancer. A number of publications have used this methodology (prior to MRC funding) from this source. This project has now produced 3 publications, in addition to several poster presentations with published abstracts, alongside further collaborations with other tech transfer companies. The partnership with LifeArc and CR-UK Discovery Labs to test a range of novel anti-cancer drugs is continuing (for a total of £735,000 until 2021) and has attracted considerable attention from the pharmaceutical industry. Boehringer Ingelheim, Pierre Fabre and Ono Pharmaceuticals are interested in the PDE platform for preclinical drug testing. This project has received 3 rounds of follow on CiC funding, generating >19-fold return on MRC CiC investment to date (Total £1.7M). Update Feb2020.
Start Year 2016
 
Title ECG EVALUATION 
Description A method for assessing the electrical function of a heart, a method for determining a subject's need for the implantation of an implantable cardioverter defibrillator or the need for administration of an anti-arrhythmic agent, and apparatus for assessing the function of the heart and a computer program product. The methods and products involve analysis of ECG. 
IP Reference WO2015150831 
Protection Patent granted
Year Protection Granted 2015
Licensed No
Impact As described in the Collaborations and Partnerships section. To be granted in Australia and USA, in national phase in 5 countries.
 
Title METHOD AND APPARATUS FOR EVALUATING CARDIAC FUNCTION 
Description The present invention relates to a method for assessing the electrical function of a heart, comprising the steps of:- (1) for each of a plurality of leads of an ECG, determining a value derived from the output of that lead and which corresponds to an action potential duration; (2) for each of the plurality of leads of the ECG, determining a value derived from the output of that lead and which corresponds to a diastolic interval; (3) for each of the plurality of leads of the ECG, determining a relationship between the determined values for action potential duration and for diastolic interval; (3) assessing the differences between the determined relationships for each of the plurality of leads. The invention further relates to apparatus and a computer program that may be used in the method. 
IP Reference WO2011117608 
Protection Patent granted
Year Protection Granted 2011
Licensed No
Impact As described in the Collaboration and Partnerships section of this form. Has recently been granted in USA (13/3/2018) and Australia (9/4/2018) in addition to China (2015) and Japan (2015) and is under review in Canada, Europe, and India.
 
Description Exhibition at ELRIG Drug Discovery 2017 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Leicester Drug Discovery team exhibited at the ELRIG DD 2017 conference in Liverpool and engaged with leaders and companies in the pharma industry to find new collaborations for ongoing projects. A new collaboration was established with UCB, which will introduce CRO-type work on haematology models. Requests were made to establish a collaboration on IgA nephropathy to test mAb products.
Year(s) Of Engagement Activity 2017
 
Description Girlguiding 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Other audiences
Results and Impact Multiple events within Girlguiding Leicestershire - 1) age appropriate hands on activities performed with girls from 4-17 to make science fun and engaging - with the purpose of promoting Science Technology Engineering and Maths (STEM) activities to young women (small groups - individual meetings and also to division/county events including camps and activity days) 2) training sessions for leaders in Girlguiding to enable/encourage them to undertake STEM activities within thier units 3) to promote Women In Science and Engineering (WISE) 4) provide positive female role models
Year(s) Of Engagement Activity 2015,2016,2017,2018
 
Description Interreg grant - Engagement with SME companies in the region 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Industry/Business
Results and Impact As part of the Interreg grant that was awarded to the University of Leicester, engagement with SME companies in the region is ongoing to improve and grow their chances to develop diagnostic tests and healthcare products. Facilitated the contact between SMEs and key opinion leaders within healthcare and politics to get the right clinical input, such as facilitate access to the relevant clinical samples or clinical trials to develop their products further.
Year(s) Of Engagement Activity 2016,2017,2018
 
Description Patient Group Talks 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact Talks about advances in drug discovery research at the University (special emphasis on lung/thoracic and haematological diseases). Typically 'after dinner style' talks with Q&A sessions.
Year(s) Of Engagement Activity 2015,2016,2017,2018
 
Description Poster presentation at BARC 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Third sector organisations
Results and Impact Dr Gareth Miles presented a poster at the British Association for Cancer Research titled ": Using an ex vivo platform of tumour explants to predict clinical response to novel anticancer drugs ".
Year(s) Of Engagement Activity 2017
 
Description Poster presentation at ELRIG Drug Discovery 2017 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Dr Gareth Miles presented a poster titled "Using an ex vivo platform of tumour explants to predict clinical response to novel anticancer drugs" at the ELRIG Drug Discovery Conference in Liverpool.
Year(s) Of Engagement Activity 2017
 
Description Workshop NC3R 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Dr Gareth Miles attended the NC3R workshop and presented a poster there, entitled "Using an ex vivo platform of tumour explants to predict clinical response to novel anticancer drugs"
Year(s) Of Engagement Activity 2017